0000950170-24-028015.txt : 20240307 0000950170-24-028015.hdr.sgml : 20240307 20240307162755 ACCESSION NUMBER: 0000950170-24-028015 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240305 FILED AS OF DATE: 20240307 DATE AS OF CHANGE: 20240307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kalif Eliyahu Sharon CENTRAL INDEX KEY: 0001798443 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 24730545 MAIL ADDRESS: STREET 1: C/O TEVA, 5 BASEL STREET, P.O. BOX 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 4951033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV STATE: L3 ZIP: 6944020 BUSINESS PHONE: 972 (3) 914-8213 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 124 DVORA HANEVI'A ST. CITY: TEL AVIV STATE: L3 ZIP: 6944020 4 1 ownership.xml 4 X0508 4 2024-03-05 0000818686 TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA 0001798443 Kalif Eliyahu Sharon C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 124 DVORA HANEVI'A ST., TEL AVIV L3 6944020 ISRAEL false true false false EVP, Chief Financial Officer true Ordinary Shares 2024-03-05 4 M false 52320 A 259854 D Ordinary Shares 2024-03-05 4 M false 21387 A 281241 D Ordinary Shares 2024-03-06 4 S false 77550 13.5154 D 203691 D Restricted Share Units 2024-03-05 4 M false 21387 0 D Ordinary Shares 21387 21390 D Restricted Share Units 2024-03-05 4 M false 52320 0 D Ordinary Shares 52320 0 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, and March 5, 2024, and 21,390 vesting on March 5, 2025. Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024. /s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif 2024-03-07